2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021.

November 23 | 2021

2cureX releases the Interim report for the third quarter of 2021 on the 25th of November 2021 and on the 26th of November CEO Fernando Andreu, Ole Thastrup (CSO) and Kenneth G. Johansen (CFO) will present and discuss the report and provide a status of the European roll-out of 2cureX’s first IndiTreat product in metastatic colorectal cancer.

Please join us on the Webinar on the 26th of November at 13:00 (CET).

Link for registration: https://www.2curex.com/2curex-webinar-registration-q3-2021/

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se